A pilot, double-blind, randomised, placebo-controlled, exploratory study to investigate the safety and effect of Calf Intestinal Alkaline Phosphatase in patients with sepsis.

AM-Pharma B.V.Rumpsterweg 63981 AK BunnikTHE NETHERLANDSTelephone: +31 (0)30 228 9 222Telefax: +31 (0)30 228 9 2200 sites32 target enrollmentTBD

ConditionsSepsis.

Overview

Phase: N/A
Intervention: Not specified
Conditions: Sepsis.
Sponsor: AM-Pharma B.V.Rumpsterweg 63981 AK BunnikTHE NETHERLANDSTelephone: +31 (0)30 228 9 222Telefax: +31 (0)30 228 9 220
Enrollment: 32
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Investigators

Sponsor

AM-Pharma B.V.Rumpsterweg 63981 AK BunnikTHE NETHERLANDSTelephone: +31 (0)30 228 9 222Telefax: +31 (0)30 228 9 220

Eligibility Criteria

Inclusion Criteria

•1\. Patients \>\= 18 years and \<\= 80 years;

Exclusion Criteria

•1\. Pregnant or lactating women;

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed

N/A

A pilot double-blind randomised controlled trial comparing two physiotherapy interventions to treat femoroacetabular impingement.Femoroacetabular impingementPhysical Medicine / Rehabilitation - PhysiotherapyMusculoskeletal - Other muscular and skeletal disorders

ACTRN12615001218583a Trobe University, La Trobe Sport and Exercise Medicine Research Centre40

Active, Not Recruiting

Phase 1

A pilot study of the use of metformin to reduce airway glucose in COPDChronic obstructive pulmonary diseaseMedDRA version: 21.1 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]

EUCTR2018-001755-12-GBImperial College40

Recruiting

N/A

The FCATFibromyalgia

NL-OMON28585eiden University Medical Center (LUMC)40

Recruiting

N/A

The LCAT studyow back pain

NL-OMON26947eiden University Medical Center (LUMC)40

Completed

N/A

•Research study to investigate the safety, tolerability and effects of multiple doses of LTI-291 in patients with Parkinson’s Disease with a GBA1 mutation.PD patients with a GBA1 mutation , movement disorder

NL-OMON23923•Lysosomal Therapeutics, Incorporated40